AeroDel and Zydus Forge Exclusive Deal for Revolutionary Respiratory Device Launch
In a significant move for India's healthcare sector, AeroDel Technology Innovations Pvt. Ltd., a Mumbai-based respiratory medical device firm, has entered into an exclusive licensing arrangement with Zydus Lifesciences Limited. This partnership is set to facilitate the pan-India commercial launch of the A202 device, rebranded as Aerolife Mini™, in March 2026. This collaboration marks a pivotal step in addressing the growing burden of chronic respiratory diseases in the country.
Addressing a Critical Healthcare Challenge
India is grappling with a rising prevalence of chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. Millions of patients depend on long-term inhaled therapies to manage symptoms, prevent exacerbations, and maintain their quality of life. However, a staggering 94% of patients commit at least one critical error while using inhaler devices, leading to suboptimal drug delivery and diminished therapeutic benefits.
Spacer devices are designed to enhance lung deposition of medications delivered via pressurised Metered Dose Inhalers (pMDIs) by minimising coordination errors. Yet, the current market offerings are largely undifferentiated, characterised by bulky designs, repetitive assembly requirements, and poor real-world adherence, especially outside home settings.
Introducing Aerolife Mini™: A Game-Changer in Inhalation Therapy
AeroDel's A202 device, now known as Aerolife Mini™, represents a breakthrough solution to a problem that has persisted since the introduction of pMDIs over six decades ago. This innovative product features a compact, foldable, and always-ready architecture that fundamentally redefines pMDI usage. Unlike traditional spacers, Aerolife Mini™ is designed to remain permanently attached to the inhaler, eliminating the need for assembly before each use.
The device is engineered to achieve superior drug deposition, enhance patient compliance, boost confidence, and offer greater convenience. Its portable and foldable form factor makes the inhaler-device combination easy to carry, supporting consistent use by patients whether at home or on the go.
Intellectual Property and Strategic Partnership
A202 is protected by a granted utility patent in India, with patent applications filed in multiple countries worldwide. Additionally, two design registrations have been applied for and granted, and trademark applications are in progress. Under the exclusive commercial arrangement, AeroDel retains full ownership of the underlying technology and intellectual property, while Zydus will spearhead the marketing and commercialisation efforts for Aerolife Mini™ across India.
This launch signifies AeroDel's second commercial partnership with Zydus Lifesciences, following the successful introduction of PEPAIR™, India's first affordable Oscillating Positive Expiratory Pressure (OPEP) device, also developed and manufactured by AeroDel.
Future Prospects and Company Vision
With an expanding portfolio of patient-centric respiratory devices, AeroDel remains committed to simplifying inhalation therapy and improving adherence. The company is actively advancing multiple device innovations tailored for Indian respiratory patients and has plans to extend its respiratory device platforms to international markets.
AeroDel Technology Innovations Pvt. Ltd. was founded by Zahir Jaffer, Shradha Sangwai, and Suraj Rajan, a team with personal experience in respiratory disease. The company focuses on designing, developing, and manufacturing affordable respiratory devices, supported by entities such as Venture Center, the Department of Science and Technology (Government of India), AIC-CCMB, the Startup India Seed Fund, and individual investors.
Zydus Lifesciences Limited, a global lifesciences company with over 29,000 employees, including 1,500 scientists, aims to empower people to live healthier lives through innovative healthcare solutions. The group has introduced several first-in-class products over the past decade, addressing unmet medical needs with vaccines, therapeutics, and new chemical entities.
